NCT06571864View on ClinicalTrials.gov

AL Amyloidosis and Anti-CD38-Daratunumab

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 2, 2022

Primary Completion Date

January 2, 2024

Study Completion Date

February 2, 2024

Conditions
Amyloidosis
Interventions
DRUG

Anti-CD38 Monoclonal Antibody

Anti-CD38 Monoclonal Antibody: Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until the 52nd week (8 more administrations)

Trial Locations (1)

10154

San Giovanni Bosco Hospital, Turin

All Listed Sponsors
lead

University of Turin, Italy

OTHER